Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Adenosine A2A Receptor Antagonist PBF-509

Known as: A2AR Antagonist PBF-509, PBF-509 
An orally bioavailable adenosine A2A receptor (A2AR) antagonist, with potential antineoplastic activity. Upon administration, A2AR antagonist PBF-509… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Leukemia develops as the result of intrinsic features of the transformed cell, such as gene mutations and derived oncogenic… Expand
  • figure 1
  • table 1
  • table 1
  • figure 2
2018
2018
9089Background: ATP is catabolized to adenosine in the tumor microenvironment, leading to excess adenosine and immunosuppressive… Expand
2017
2017
BACKGROUND: Therapeutic strategies targeting immune checkpoint proteins have led to significant responses in patients with… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2014
Review
2014
  • A. Pinna
  • CNS Drugs
  • 2014
  • Corpus ID: 30098173
Neurotransmitters other than dopamine, such as norepinephrine, 5-hydroxytryptamine, glutamate, adenosine and acetylcholine, are… Expand
  • figure 1
  • table 1